Investor Relations

Wether you are an investor or a prospecting partner, we're here to help you understand our work and objectives.

Market Opportunity

LPR is estimated to affect more than 20% of the United States population.

N-Zyme Biomedical seeks to provide a much-needed treatment for the millions of people in the US and worldwide that suffer from LPR.

$26 Billion/Year Spent On PPIs For LPR
PPI Placebo-Controlled Trials Failed To Demonstrate Efficacy
No Medical Therapy Currently Available
Multiple Patent Applications Filed
FDA/IND Phase III Clinical Trial Approval Received
Institutional Review Board (IRB) Phase III Clinical Trial Approval Received
Regulatory Approvals & High-value IP

The disclosure provides a composition comprising of an inhaled and oral sustained-release formulation of an HIV protease inhibitor capable of inhibiting pepsin and a pharmaceutically acceptable carrier.

» Request Investor Presentation for details
excellence in leadership

Founded by Franco Vigile, an enterpreneur, and Nikki Johnston, Ph.D., who dedicated her career to LPR research.

» Meet our team
request investor package

Enter your email information to receive our investor presentation.

Send Request
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Press Releases
© 2021 N-Zyme Biomedical Inc.
All Rights Reserved